InsiderTrades

Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001787306-24-000018 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-02-15 2024-02-13 ARQT Matsuda Masaru See Remark A - Grant — +119.5K 194.2K +160% —
DM 2024-02-15 2024-02-13 ARQT Matsuda Masaru See Remark D - Sale to Iss — -276.1K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-13 A A 74,000 — 148,634 D — — (F1) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 3, 2022, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024.
2 Common Common Stock 2024-02-13 A A 17,650 — 166,284 D — — (F2) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
3 Common Common Stock 2024-02-13 A A 27,900 — 194,184 D — — (F3) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024.
4 Derivative Stock Option (right to buy) 2024-02-13 D D 185,000 — 0 D $22.79 · — to 2032-01-03 185,000 Common Stock (F1) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 3, 2022, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. (F4) The canceled option vested as to 1/4 of the total shares on January 3, 2023, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on January 3, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
5 Derivative Stock Option (right to buy) 2024-02-13 D D 55,800 — 0 D $15.82 · — to 2033-03-02 55,800 Common Stock (F3) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023. and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. (F6) The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
6 Derivative Stock Option (right to buy) 2024-02-13 D D 35,300 — 0 D $17.67 · — to 2032-03-03 35,300 Common Stock (F2) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. (F5) The canceled option vest as to 1/48 of the shares subject to the option vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.